The international model and diabetes advocate on career, self-confidence and being the change she wants to see.

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

If you have $2,000 to invest right now, here are two top growth stocks to consider. DexCom (NASDAQ: DXCM) is one of the ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

Q4 2024 Earnings Call Transcript February 13, 2025 DexCom, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.4792. Operator: Thank you for standing by. My name is ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose level tracking, giving users actionable insights. The company has been concentrating on product development ...

Additionally, regulatory progress with the 15-day G7 CGM could provide a long-term boost. While challenges such as competitive pressures and channel mix shifts remain, DexCom appears well ...

The Stelo has a 15-day wear time before the sensor needs to be replaced, similar to DexCom's flagship G7 CGM, which has a 10-day wear time. While short-term factors such as above-average ...